Cellino
AI-driven biomanufacturing for personalized stem cell therapies
Cellino tackles the scalability bottleneck in personalized stem cell therapy with a bold AI+laser approach. Its autonomous biomanufacturing could disrupt the field if clinical trials succeed, but it's pre-revenue and pre-product. Buyers seeking immediate tools should look elsewhere.
Verified 18d ago · liveness 75/100 · cite: rightaichoice.com/tools/cellino
- Scalable biomanufacturing for autologous cell therapies in R&D settings
- Personalized stem cell therapy development for degenerative diseases
- Hospital-based localized cell manufacturing (future potential)
- Patients seeking immediate treatments (still in development)
- Off-the-shelf allogeneic therapies (focus is autologous)
- Simple cell culture without AI or automation
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Cellino if you need a commercially available cell therapy manufacturing platform today or if your focus is on off-the-shelf allogeneic therapies.
Cellino has no public pricing. As a pre-commercial platform targeting high-complexity personalized cell therapy manufacturing, it is likely to be costly and oriented toward large biopharma partners, not small labs.
In short
Cellino — AI-driven biomanufacturing for personalized stem cell therapies. Best for Scalable biomanufacturing for autologous cell therapies in R&D settings, Personalized stem cell therapy development for degenerative diseases, Hospital-based localized cell manufacturing (future potential). Contact Sales pricing.
Viability Score
How likely is Cellino to still be operational in 12 months? Based on 4 signals — momentum (how recently it shipped), wrapper dependency, revenue model, and web presence.
Last calculated: July 2026
How we score →Key Features
- Deep learning AI for reproducible biomanufacturing
- Cellinoverse digital environment for in silico simulation
- Laser-generated bubbles for precise cell removal
- Closed-loop image-guided optical bioprocess
- Nebula modular cassette-based platform
- Scalable production of biologically younger stem cells
- Personalized one-time treatments from patient's own cells
- Eliminates need for immunosuppression
- Autonomous cell processing minimizing human variability
- Modular systems for hospital localization
- AI algorithms for consistent, scalable biomanufacturing
- Laser cell management for controlling cell density
- Demonstrated across diverse patient backgrounds (2026 study)
About Cellino
Cellino is a biotechnology company combining deep learning, laser optics, and closed-loop optical bioprocesses to automate the production of personalized stem cell therapies. Its Nebula platform compresses traditional biomanufacturing into modular, cassette-based systems deployable in hospitals or large-scale foundries, targeting chronic degenerative diseases like Parkinson's, diabetes, and macular degeneration. The platform uses AI algorithms for reproducible biomanufacturing, a Cellinoverse digital environment for in silico simulation, and laser-generated bubbles for precise cell removal. Unlike manual methods, Cellino's approach minimizes human variability and consistency issues. The company was named one of Fast Company's Most Innovative Companies of 2026 and demonstrated tissue manufacturing across diverse patient backgrounds with Polyphron. Cellino remains pre-commercial with no market-ready product or pricing disclosed, positioning itself as a long-term bet for scalable autologous cell therapy.
Behind the Verdict
Cellino's vision is compelling: replace manual, error-prone cell culture with a fully autonomous, AI-guided platform. The Nebula platform's modular cassettes and laser-precision cell removal are genuinely novel, and the Cellinoverse for in silico simulation suggests a mature engineering approach. However, this is a bet on future results. There's no commercial product, no published pricing, and no clinical trial data on the site (only a partnership announcement). If you're a pharma R&D leader scouting next-gen manufacturing tech, put Cellino on your radar for 2027+. For now, it's a research project, not a procurement option. Compared to Dendric (AI-driven cell therapy discovery) or Mogrify (reprogramming platform), Cellino is further upstream in process automation. Real-world caveat: even if the tech works, regulatory hurdles for autologous therapies are steep. We'd give it time.
Researching Cellino? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas Cellino actually fits — and what changes day-one when you adopt it.
You need to produce consistent iPSC batches for a Parkinson's therapy candidate. You deploy Cellino's Nebula platform with AI-driven optical bioprocess.
Outcome: You achieve reproducible cell quality with minimal human variability, accelerating preclinical development.
You want to simulate and optimize your cell culture protocol in silico before physical experiments.
Outcome: You use Cellinoverse to run digital twins of your workflow, reducing trial-and-error and reagent costs.
Use Cases
- Automate iPSC manufacturing for personalized cell replacement therapies targeting degenerative diseases.
- Produce consistent, high-quality stem cell batches for research or clinical trials with AI-guided optical control.
- Scale up cell therapy production from lab to commercial volumes using modular, cassette-based Nebula systems.
- Eliminate manual variability in cell culture by deploying closed-loop image-guided bioprocesses.
- Establish localized cell therapy manufacturing hubs in hospitals to increase patient access.
- Simulate and optimize biomanufacturing workflows in silico using the Cellinoverse digital twin.
Models Under the Hood
as of 2026-07-14
Limitations
- Cellino's platform is not yet commercially available; the company is in development and partnership phases.
- No pricing or API access is currently public.
- The technology requires deep expertise in cell biology and automation, and it may be several years before regulatory clearance and widespread deployment.
as of 2026-06-25
Where the pricing makes sense
The company stage and team size where Cellino's pricing actually pencils out — and where peers do it cheaper.
Cellino has no public pricing. As a pre-commercial platform targeting high-complexity personalized cell therapy manufacturing, it is likely to be costly and oriented toward large biopharma partners, not small labs.
Setup time & first value
How long it actually takes to get something useful out of Cellino — broken out by persona, not the marketing-page minute.
Setup time is unknown publicly. As a modular platform requiring integration with existing cell culture infrastructure, expect months for installation and validation in a partnership context.
Resources & Guides
Tutorials & Learning
Official links
Frequently Asked Questions
Categories
Best-of guides
Used Cellino? Help shape our editorial sentiment research.